The value-for-money of adjuvant aromatase inhibitors: time to put the debate to rest?

The adoption of costly treatments in public health care systems, such as exists in Canada, must take into account their “clinical benefit to side effect” profiles and “value for money” in an attempt to maximize health gains within current budget constraints [...]

Saved in:
Bibliographic Details
Published in:Current oncology (Toronto) 2015-04, Vol.22 (2), p.77-79
Main Authors: Younis, T, Groom, A
Format: Article
Language:English
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c378t-d768779d3c44f10451b28b08e46db6881ab41d6a2323f363075dc7450298a74c3
cites
container_end_page 79
container_issue 2
container_start_page 77
container_title Current oncology (Toronto)
container_volume 22
creator Younis, T
Groom, A
description The adoption of costly treatments in public health care systems, such as exists in Canada, must take into account their “clinical benefit to side effect” profiles and “value for money” in an attempt to maximize health gains within current budget constraints [...]
doi_str_mv 10.3747/co.22.2579
format article
fullrecord <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_4399613</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1675873772</sourcerecordid><originalsourceid>FETCH-LOGICAL-c378t-d768779d3c44f10451b28b08e46db6881ab41d6a2323f363075dc7450298a74c3</originalsourceid><addsrcrecordid>eNpVkVtLxDAQhYMo7np58QdIHkXomls7iQ-KiDdY8GX3OaRp6lbaZk3SBf-91VXRpxlmPs4M5yB0QsmMg4AL62eMzVgOagdNKVCZATC1O_ZUyYyQnE3QQYyvhHAOAPtownJFpCJiipaLlcMb0w4uq33IOt-7d-xrbKrXYWP6hE3wnUkmOtz0q6Zskg_xEqemczh5vB4STqNC5UqTvibBxXR9hPZq00Z3_F0P0fL-bnH7mM2fH55ub-aZ5SBTVkEhAVTFrRA1JSKnJZMlkU4UVVlISU0paFUYxhmvecEJ5JUFkROmpAFh-SG62uquh7JzlXV9CqbV69B0Jrxrbxr9f9M3K_3iN1pwpQrKR4Gzb4Hg34bxdd010bq2Nb3zQ9S0gFzC6Bob0fMtaoOPMbj69wwl-jMHbb1mTH_mMMKnfx_7RX-M5x8KTINz</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1675873772</pqid></control><display><type>article</type><title>The value-for-money of adjuvant aromatase inhibitors: time to put the debate to rest?</title><source>PubMed Central</source><creator>Younis, T ; Groom, A</creator><creatorcontrib>Younis, T ; Groom, A</creatorcontrib><description>The adoption of costly treatments in public health care systems, such as exists in Canada, must take into account their “clinical benefit to side effect” profiles and “value for money” in an attempt to maximize health gains within current budget constraints [...]</description><identifier>ISSN: 1198-0052</identifier><identifier>ISSN: 1718-7729</identifier><identifier>EISSN: 1718-7729</identifier><identifier>DOI: 10.3747/co.22.2579</identifier><identifier>PMID: 25908904</identifier><language>eng</language><publisher>Canada: Multimed Inc</publisher><ispartof>Current oncology (Toronto), 2015-04, Vol.22 (2), p.77-79</ispartof><rights>Copyright © 2015 Multimed Inc. 2015</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c378t-d768779d3c44f10451b28b08e46db6881ab41d6a2323f363075dc7450298a74c3</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC4399613/pdf/$$EPDF$$P50$$Gpubmedcentral$$H</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC4399613/$$EHTML$$P50$$Gpubmedcentral$$H</linktohtml><link.rule.ids>230,315,733,786,790,891,27957,27958,53827,53829</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/25908904$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Younis, T</creatorcontrib><creatorcontrib>Groom, A</creatorcontrib><title>The value-for-money of adjuvant aromatase inhibitors: time to put the debate to rest?</title><title>Current oncology (Toronto)</title><addtitle>Curr Oncol</addtitle><description>The adoption of costly treatments in public health care systems, such as exists in Canada, must take into account their “clinical benefit to side effect” profiles and “value for money” in an attempt to maximize health gains within current budget constraints [...]</description><issn>1198-0052</issn><issn>1718-7729</issn><issn>1718-7729</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2015</creationdate><recordtype>article</recordtype><recordid>eNpVkVtLxDAQhYMo7np58QdIHkXomls7iQ-KiDdY8GX3OaRp6lbaZk3SBf-91VXRpxlmPs4M5yB0QsmMg4AL62eMzVgOagdNKVCZATC1O_ZUyYyQnE3QQYyvhHAOAPtownJFpCJiipaLlcMb0w4uq33IOt-7d-xrbKrXYWP6hE3wnUkmOtz0q6Zskg_xEqemczh5vB4STqNC5UqTvibBxXR9hPZq00Z3_F0P0fL-bnH7mM2fH55ub-aZ5SBTVkEhAVTFrRA1JSKnJZMlkU4UVVlISU0paFUYxhmvecEJ5JUFkROmpAFh-SG62uquh7JzlXV9CqbV69B0Jrxrbxr9f9M3K_3iN1pwpQrKR4Gzb4Hg34bxdd010bq2Nb3zQ9S0gFzC6Bob0fMtaoOPMbj69wwl-jMHbb1mTH_mMMKnfx_7RX-M5x8KTINz</recordid><startdate>20150401</startdate><enddate>20150401</enddate><creator>Younis, T</creator><creator>Groom, A</creator><general>Multimed Inc</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>20150401</creationdate><title>The value-for-money of adjuvant aromatase inhibitors: time to put the debate to rest?</title><author>Younis, T ; Groom, A</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c378t-d768779d3c44f10451b28b08e46db6881ab41d6a2323f363075dc7450298a74c3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2015</creationdate><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Younis, T</creatorcontrib><creatorcontrib>Groom, A</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Current oncology (Toronto)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Younis, T</au><au>Groom, A</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>The value-for-money of adjuvant aromatase inhibitors: time to put the debate to rest?</atitle><jtitle>Current oncology (Toronto)</jtitle><addtitle>Curr Oncol</addtitle><date>2015-04-01</date><risdate>2015</risdate><volume>22</volume><issue>2</issue><spage>77</spage><epage>79</epage><pages>77-79</pages><issn>1198-0052</issn><issn>1718-7729</issn><eissn>1718-7729</eissn><notes>ObjectType-Article-1</notes><notes>SourceType-Scholarly Journals-1</notes><notes>ObjectType-Feature-2</notes><notes>content type line 23</notes><abstract>The adoption of costly treatments in public health care systems, such as exists in Canada, must take into account their “clinical benefit to side effect” profiles and “value for money” in an attempt to maximize health gains within current budget constraints [...]</abstract><cop>Canada</cop><pub>Multimed Inc</pub><pmid>25908904</pmid><doi>10.3747/co.22.2579</doi><tpages>3</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 1198-0052
ispartof Current oncology (Toronto), 2015-04, Vol.22 (2), p.77-79
issn 1198-0052
1718-7729
1718-7729
language eng
recordid cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_4399613
source PubMed Central
title The value-for-money of adjuvant aromatase inhibitors: time to put the debate to rest?
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-09-21T19%3A40%3A33IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=The%20value-for-money%20of%20adjuvant%20aromatase%20inhibitors:%20time%20to%20put%20the%20debate%20to%20rest?&rft.jtitle=Current%20oncology%20(Toronto)&rft.au=Younis,%20T&rft.date=2015-04-01&rft.volume=22&rft.issue=2&rft.spage=77&rft.epage=79&rft.pages=77-79&rft.issn=1198-0052&rft.eissn=1718-7729&rft_id=info:doi/10.3747/co.22.2579&rft_dat=%3Cproquest_pubme%3E1675873772%3C/proquest_pubme%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c378t-d768779d3c44f10451b28b08e46db6881ab41d6a2323f363075dc7450298a74c3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=1675873772&rft_id=info:pmid/25908904&rfr_iscdi=true